^
Association details:
| Biomarker: | WT1 underexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience
Published date:
11/20/2020
Excerpt:
We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML)...Six patients responded to the treatment (31.6%) with 3 complete remissions (15.8%). Five patients had stable disease, and 8 patients did not show any response...Peripheral WT1 mRNA levels mostly decreased over time in the responders.
DOI:
10.1007/s12185-020-03023-4
